Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Hexarelin
Beginner tier: 100 mcg, daily · community consensus
Also known as: Examorelin, HEX, EP-23905
Six amino acids double the growth hormone release of GHRH at the same IV dose [1]. GHRP-2 matched that pulse at equal doses [3]. Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic growth hormone releasing peptide that hits both the pituitary GHS-R1a receptor and a separate cardiac CD36 receptor. Other GHRPs share that dual action profile [12]. It reached Phase II clinical trials for GH deficiency and congestive heart failure in the 1990s before development stopped. The tradeoff is real: hexarelin raises cortisol and prolactin, about as much as GHRP-2 does at equal doses [3]. Receptor desensitization limits continuous use to roughly four weeks. Experienced users run it in short, intense cycles stacked with a GHRH for maximum output.
What Is Hexarelin?
Growth hormone release about twice that of GHRH at the same IV dose. Ghigo and colleagues measured this in 12 healthy young volunteers, with a dose-dependent response after subcutaneous injection too [1]. GHRP-2 matched hexarelin's GH pulse at equal IV doses in two head-to-head studies [3][9]. Hexarelin is a synthetic hexapeptide GHS-R1a agonist, sometimes listed under CAS 140703-51-1, that mimics ghrelin at both the pituitary and hypothalamus to trigger growth hormone release.
Hexarelin also binds a second target, the CD36 scavenger receptor. Bodart and colleagues found this second binding site in rat heart tissue in 1999 [2] and identified it as CD36 in 2002 [7]. Through CD36, hexarelin produces anti-fibrotic cardiac effects and preserves cell contractility during ischemia, completely independent of the GH axis. Other GHRPs share this dual profile. A 2017 review describes the GHRP family as binding both GHS-R1a and CD36 [12].
The practical reality is a 4-week ceiling. Hexarelin's high GHS-R1a binding affinity drives receptor downregulation faster than any other peptide in this class. Community protocols converge on 4 weeks on, 2 to 4 weeks off, with many users adding 5-on/2-off weekly cycling within each block to slow desensitization further. The typical stack pairs 100 to 200 mcg hexarelin with 100 mcg CJC-1295 (no DAC) co-injected subcutaneously at bedtime.
About 311 PubMed papers cover hexarelin. Most are mechanistic or short-term pharmacological work, not long-term therapeutic trials. It reached Phase II for adult GH deficiency and heart failure before development was abandoned, likely because desensitization made chronic dosing impractical. It was never submitted for FDA approval and remains a research-only compound. Community experience across dozens of Reddit threads tracks closely with the published pharmacology; the 100 to 200 mcg per injection dosing range is where most users land.
How Hexarelin Works
Hexarelin binds GHS-R1a at the anterior pituitary with higher affinity than any other growth hormone releasing peptide. That binding triggers a calcium-dependent signaling cascade in somatotroph cells, producing a GH pulse within 30 minutes of subcutaneous injection. Unlike ipamorelin, which is selective for GHS-R1a, hexarelin also activates ACTH release from the pituitary. This cross-reactivity explains the cortisol and prolactin elevations that Arvat and colleagues measured in healthy adults [3]. GHRP-2 at matched doses raised them by similar amounts in the same study.
The second receptor is what sets hexarelin apart. Bodart's group identified CD36, a scavenger receptor expressed on cardiomyocytes, as a direct hexarelin binding target [7]. Through CD36, hexarelin reduces cardiac fibrosis, preserves cell shortening during ischemia-reperfusion injury, and regulates intracellular calcium handling. A 2018 mouse study confirmed that hexarelin treatment preserves myocardial function and reduces fibrosis after acute myocardial infarction [4]. These cardiac effects operate entirely independently of GH release.
Plasma half-life runs approximately 55 to 70 minutes after subcutaneous injection, with GH peak occurring around 30 minutes post-dose. Oral bioavailability is only about 0.3%, making subcutaneous injection the only practical route. The short half-life means each injection produces a discrete GH pulse rather than sustained elevation; that pulsatile pattern mimics natural physiology better than continuous GH administration.
Hexarelin Benefits
- Hexarelin benefits center on short-cycle GH output and a cardiac mechanism through the CD36 receptor.
- Releases about twice the GH of GHRH at the same IV dose [1], and the response nears its ceiling at 1 to 2 mcg/kg IV [5]. GHRP-2 matched it head to head at equal IV doses [3][9].
- Binds the CD36 cardiac receptor independently of GH release. Mouse models show preserved myocardial function and reduced fibrosis after acute infarction [4]. Other GHRPs bind CD36 too, per a 2017 review of the peptide family [12].
- Sleep architecture improves with bedtime dosing. GH promotes slow-wave sleep, and community reports consistently flag deeper sleep as one of the first noticeable effects within the opening 2 to 3 doses.
- Complementary with GHRH peptides through dual receptor activation. Pairing hexarelin (GHS-R1a) with CJC-1295 no DAC (GHRHR) produces a GH pulse larger than either compound alone.
- Body recomposition signal within a 4-week window. Users report reduced abdominal fat and improved muscle fullness by weeks 3 to 4, particularly at the intermediate 200 mcg twice daily protocol.
- Recovery from training accelerates during on-cycle weeks. Community consensus places noticeable recovery improvement at the 1 to 2 week mark, consistent with the IGF-1 elevation timeline from sustained GH pulsing.
Hexarelin: Science vs Community Consensus
Potent GHS-R1a agonist in human dose-response trials: about twice the GH release of GHRH at 1 mcg/kg IV [1].
Read the evidence (key study, limitations)
Reached Phase II clinical trials for adult GH deficiency and congestive heart failure (1990s); development discontinued, likely due to desensitization limiting long-term utility. Never FDA-approved. Rat heart studies found a distinct cardiac hexarelin receptor [2], later identified as CD36 [7]. Hexarelin protected rat hearts from ischemia/reperfusion injury, partly through GHS-R1a and, one group concluded, largely through CD36 [6][8], not validated in human clinical endpoints. GH, prolactin, ACTH and cortisol rises matched GHRP-2 at equal IV doses in two small human studies [3][9]. Head-to-head human data against GHRP-6 or ipamorelin are lacking. ~311 PubMed papers; the majority are mechanistic or short-term pharmacological studies, not therapeutic RCTs.
Ghigo et al. 1994 (PMID 8126144): dose-response and route comparison in healthy men; established SC efficacy and dose ceiling. Bodart et al. 1999 (PMID 10532947): found a new 84 kDa cardiac hexarelin receptor that MK-0677 does not bind; Bodart et al. 2002 (PMID 11988484) identified it as CD36. Arvat et al. 1997 (PMID 9285939): in 6 healthy young adults, hexarelin and GHRP-2 at equal IV doses raised prolactin, ACTH and cortisol by similar amounts.
No long-term therapeutic RCT for SC dosing. Desensitization mechanism documented in animals; formal human desensitization kinetics unpublished. Oral bioavailability ~0.3% (clinical trial data): not a practical route. SC bioavailability not formally quantified in humans (estimated 60-70% from mechanistic extrapolation). All cardioprotective data from animal models or in vitro: no human clinical endpoints confirmed.
Highly respected but niche and considered an advanced GHRP.
Read the reports (what users report 5, common issues 5)
Strong consensus on it producing the largest GH pulse of any GHRP ("nothing else touches it for raw GH output") but most experienced users ultimately migrate to ipamorelin for long-term use due to cleaner hormonal profile and no desensitization. Hexarelin is reserved for short, intense cycles where maximum GH output is the priority. CD36 cardioprotective mechanism is frequently cited as a differentiator.
- Community reports call it the strongest raw GH pulse of any GHRP
- Cardioprotective CD36 mechanism: a frequently cited differentiator
- Pronounced sleep quality improvement with bedtime dosing
- Rapid body recomposition signal in short 4-week cycles
- Synergistic with GHRH for amplified GH pulse vs. either alone
- Receptor desensitization: fastest of any GHRP; 4-week cap limits sustained use
- Community reports rank its cortisol and prolactin rises above ipamorelin and GHRP-2
- Community often reports "hexarelin stopped working": almost always due to exceeding 4-week continuous use
- More side effects than ipamorelin drives users to cleaner alternatives for long-term protocols
- Strict fasting window required: blunting from food is significant
Science and community agree on GHS-R1a mechanism, a strong GH pulse, cortisol/prolactin elevation, and the principle of receptor desensitization requiring cycling. Community has independently converged on 4-week on/off cycling and the CJC-1295 no DAC stack: both mechanistically justified. Community SC dosing (100-300 mcg) extrapolates beyond any published clinical therapeutic RCT; 300 mcg 2×/day exceeds clinical dose-response ceiling. Science and community split on ranking. Community reports put hexarelin's GH pulse and its cortisol and prolactin rises above GHRP-2's. Two human studies at equal IV doses found all of them similar (PMID 9285939, 10195374). Community reports also treat CD36 as hexarelin's edge over other GHRPs; a 2017 review places CD36 binding across the GHRP family (PMID 28469491).
Hexarelin Dosage Guide
Stack hexarelin with a GHRH, not another GHRP. The single most common mistake is pairing it with ipamorelin or GHRP-2. Both hit the same GHS-R1a receptor. You're wasting one compound. The correct partner is CJC-1295 (no DAC) or sermorelin, co-injected simultaneously.
Reconstitution math for a 5mg vial: add 2 mL bacteriostatic water. That gives you 2,500 mcg/mL. On a U-100 insulin syringe, 4 units equals 100 mcg, 8 units equals 200 mcg, 12 units equals 300 mcg. For a 2mg vial with 2 mL BAC water, you get 1,000 mcg/mL; 10 units equals 100 mcg.
Fasting compliance matters more with hexarelin than most peptides. Carbohydrates and fats raise somatostatin, which blunts the GH pulse considerably. No food 30 minutes before or after injection at minimum. Two hours post-meal is better. If your IGF-1 isn't moving after 4 weeks, check your fasting window before blaming the product.
Refrigerate reconstituted vials and use within 3 to 4 weeks.
Cycling Protocol
Hexarelin desensitizes GHS receptors with continuous use. Cycle 4 weeks on, 2-4 weeks off to maintain GH responsiveness. Some protocols use 5 days on, 2 days off within each on-cycle week.
Hexarelin has the highest GHS-R1a binding affinity of any GHRP. This high-affinity binding drives GHS-R1a downregulation and β-arrestin-mediated receptor internalization faster than any other peptide in this class. Desensitization of the GH pulse is the primary documented failure mode with continuous hexarelin use: onset typically within 4-6 weeks of daily dosing, with the community converging on a strict 4-week on / 2-4 week off protocol as the standard cycling approach. The 5-on/2-off within each week is a secondary mitigation strategy layered on top of the 4-week gross cycle. No long-term human receptor density data exists; the cycling rationale is mechanistically sound but the specific off-period duration is community convention rather than clinically validated.
- Reduced post-injection warmth and tingling: a reliable early indicator that was present in the first 1-2 weeks and is now diminishing
- Sleep improvement effect declining after weeks 3-4 of continuous dosing
- IGF-1 plateauing or declining despite continued fasted protocol and correct dosing
- Appetite stimulation post-injection becoming less pronounced (ghrelin pathway downregulating)
Or use the universal Peptide Calculator for any peptide.
Hexarelin Protocols by Goal
Expected: Sleep quality improvement within weeks 1-2; recovery improvement by weeks 2-3; modest body composition changes (reduced abdominal fat, improved muscle fullness) by end of 4-week cycle
Monitor: Baseline IGF-1 before starting; recheck at week 4. Fasting glucose at baseline.
How to Inject Hexarelin
- 1Reconstitute the vial
For a 5mg vial, slowly inject 2 mL bacteriostatic water down the inside wall of the vial. Do not shake. Swirl gently until the powder dissolves completely. This gives you 2,500 mcg per mL.
- 2Step 2
Draw your dose using a U-100 insulin syringe (29-31 gauge, 0.5 inch needle). For 100 mcg, draw to the 4-unit mark. For 200 mcg, draw to 8 units. For 300 mcg, draw to 12 units.
- 3Step 3
Choose your injection site: abdomen (2 inches from the navel) or the fatty tissue on the outer thigh. Rotate sites with each injection.
- 4Clean the injection site with an alcohol swab
Pinch a fold of skin, insert the needle at a 45-degree angle, inject slowly, hold for 5 seconds, then withdraw.
- 5Timing matters
Best timing is 30 to 60 minutes before bed to amplify the natural nocturnal GH pulse. For twice-daily protocols, the morning dose should be on waking and fully fasted. Keep a minimum of 3 to 4 hours between injections.
- 6Step 6
If stacking with CJC-1295 (no DAC), draw both peptides into the same syringe and co-inject simultaneously. Do not pre-mix vials.
- 7Step 7
Store the reconstituted vial in the refrigerator at 2 to 8 degrees Celsius. Use within 3 to 4 weeks. Never freeze reconstituted solution.
Hexarelin Stacking Protocols
Works With
Primary and near-universal stack. GHRH (CJC-1295 no DAC) + GHRP (hexarelin) activates dual pituitary receptor pathways, GHRHR + GHS-R1a, producing a synergistic GH pulse significantly larger than either alone. Co-injected simultaneously to capture the synergistic window.
100 mcg CJC-1295 (no DAC) co-injected with 100-200 mcg hexarelin SC, once or twice daily, fasted
Lower-cost alternative GHRH for the hexarelin stack. Shorter half-life than CJC-1295 (no DAC), otherwise similar synergistic mechanism via GHRHR activation. Preferred by users seeking lower cost or softer GHRH stimulus.
100-300 mcg sermorelin + 100-200 mcg hexarelin SC, co-injected, once or twice daily fasted
Concurrent tissue repair stack: separate mechanism from GH pathway. GH elevation from hexarelin complements BPC-157 angiogenic and healing signaling in injury recovery protocols. Often used in the intermediate/advanced cycle off-period or alongside.
Systemic recovery stack. TB-500 actin-binding and cell migration support combined with hexarelin GH-mediated anabolic signaling in injury and post-surgery recovery protocols.
Avoid
Both hexarelin and ipamorelin bind the same GHS-R1a receptor. Co-administration provides no additive GH benefit and accelerates receptor desensitization. Choose one GHRP and stack it with a GHRH peptide instead: the most common hexarelin mistake per community consensus.
Do not combineSame GHS-R1a receptor. Hexarelin already has the highest binding affinity of any GHRP. At equal doses, it and GHRP-2 raise cortisol and prolactin by similar amounts (PMID 9285939). Combining them compounds these side effects with no additional GH benefit from dual GHS-R1a occupancy.
Do not combineSame GHS-R1a receptor. Stacking hexarelin + GHRP-6 is redundant. GHRP-6 adds intense hunger stimulation and cortisol burden with no additive GH benefit over hexarelin alone.
Do not combineCombining GH secretagogues with exogenous recombinant HGH saturates the GH/IGF-1 axis and suppresses endogenous pulsatility. Eliminates the primary rationale for secretagogue use. Dramatically increases IGF-1 overshoot risk.
Do not combineEstimated Cost
Pricing updated 2026-04-09
Hexarelin Side Effects
Cortisol and prolactin elevation are the primary safety concerns with hexarelin. Community reports often rank it the worst GHRP for both. The human head-to-head tests against GHRP-2 don't back that ranking. Arvat's group gave both at equal IV doses in two small studies, and prolactin, ACTH and cortisol rose by similar amounts [3][9]. At the beginner 100 mcg once daily dose, the cortisol bump is transient and typically returns to baseline within 2 to 3 hours post-injection. Rahim's group tracked cortisol in adults through 16 weeks of 1.5 mcg/kg twice daily, about 105 mcg at 70 kg [10]. The cortisol response to the morning injection was lower at week 16 than at baseline, and it recovered 4 weeks after stopping. The ACTH response, basal cortisol and 24-hour urinary free cortisol did not change. A one-day study in 6 young men found two or three injections left 24-hour cortisol, ACTH and prolactin output unchanged [11]. The aggressive 300 mcg twice daily protocol runs about three times Rahim's dose and lacks long-term data. Community reports at that dose describe disrupted sleep, irritability and shifts in fat distribution, which users blame on cortisol.
Prolactin follows a similar dose-dependent pattern. At lower doses, the spike is brief and unlikely to produce symptoms. Over Rahim's 16 weeks of twice-daily dosing, the prolactin response did not change [10]. At higher twice-daily doses, community reports describe libido changes and, rarely, early gynecomastia signs. Checking prolactin at baseline and at week 4 is standard practice for anyone running intermediate or advanced protocols. Some users add low-dose cabergoline during aggressive cycles, though clinical backing for that approach in this context is thin.
GHS-R1a receptor desensitization is not a side effect in the traditional sense, but it is the most common reason hexarelin "stops working." High-affinity binding drives beta-arrestin-mediated receptor internalization faster than GHRP-2, GHRP-6, or ipamorelin. The community figured this out before any formal study characterized the kinetics in humans. Four weeks of continuous daily dosing is the practical limit; beyond that, GH pulse magnitude drops noticeably. Receptor density recovers over 2 to 4 weeks off.
Water retention and mild edema are common GH-class effects. At higher doses, fluid accumulation in the carpal tunnel can produce hand tingling, numbness, or grip weakness. These are early carpal tunnel symptoms. If they persist beyond a few days at a reduced dose, stopping the cycle entirely and allowing 4 or more weeks for resolution is the right call.
Appetite increase occurs through the ghrelin pathway. It's less intense than GHRP-6, but still present, especially at 200 mcg and above. This can actually disrupt the fasting window required for proper dosing if not managed. Shifting the bedtime dose to 3 or more hours after dinner helps.
Post-injection flushing and tingling within 10 to 20 minutes is a GH flush effect and is harmless. It's actually a useful signal: when the flush stops appearing in later weeks, it often indicates desensitization has begun.
Hexarelin has not been studied in pregnant or breastfeeding individuals. GH and IGF-1 elevation carry theoretical risks for fetal development and should be avoided entirely. Anyone with active malignancy, pituitary tumors, intracranial hypertension, or uncontrolled diabetes should not use hexarelin. GH elevation impairs glucose tolerance and may promote tumor growth through the IGF-1 axis.
When to see a doctor: persistent carpal tunnel symptoms beyond one week, fasting glucose climbing above 125 mg/dL, any signs of prolactin elevation (libido changes, breast tissue changes), or edema that doesn't resolve with dose reduction.
Common Issues & Solutions
No IGF-1 movement after 4-6 weeks: Most common cause is eating within 30-60 min before/after injection: carbohydrates and fats raise somatostatin and blunt the GH pulse significantly. Verify fasting compliance before questioning product quality or dosing.
GH response decreasing week over week ("hexarelin stopped working"): Classic GHS-R1a desensitization. Implement 5-on/2-off weekly schedule immediately; if already past 4 weeks continuous, stop for at least 2 weeks minimum (4 preferred) before resuming. Receptor sensitivity typically restores within 2-4 weeks off.
Hand tingling, numbness, or grip weakness: Early carpal tunnel symptoms from GH-mediated fluid retention in the carpal tunnel. Reduce dose or injection frequency immediately. If symptoms persist beyond 1 week at lower dose, discontinue and allow 4+ weeks for GH-related edema to resolve.
Sleep disrupted despite bedtime dosing or cortisol-like symptoms (fat gain, irritability): Hexarelin raises ACTH and cortisol about as much as GHRP-2 does at equal doses [3]. At aggressive doses (300 mcg 2×/day) this is clinically relevant. Check AM cortisol; consider dose reduction or switching to ipamorelin for subsequent cycles.
Post-injection intense hunger: Less than GHRP-6 but still present: particularly at higher doses. This is a ghrelin-pathway side effect. If hunger disrupts fasting compliance, shift bedtime dose later (post-dinner, 3+ hours fasted) or consider switching to ipamorelin for cleaner dosing.
Ask AI about this page
Ask AI for a second opinion on Hexarelin dosing and side effects
Contraindications
- Active malignancy or history of cancer (GH and IGF-1 elevation may promote tumor growth)
- Pregnancy or breastfeeding (insufficient safety data in humans)
- Severe cardiac arrhythmias (requires cardiac monitoring despite cardioprotective research)
- Uncontrolled diabetes or significant insulin resistance (GH elevation impairs glucose tolerance)
- Known hypersensitivity to hexarelin or related GH secretagogue peptides
- Active pituitary tumors or intracranial hypertension
Drug Interactions
- Exogenous growth hormone (HGH): concurrent use risks supraphysiological GH levels and amplified side effects
- Glucocorticoids (prednisone, dexamethasone): may blunt GH release and reduce hexarelin efficacy
- Insulin: combined GH elevation can worsen glucose tolerance; monitor blood sugar closely
- Somatostatin analogs (octreotide): directly oppose GH release and will negate hexarelin effects
- Testosterone and estrogen compounds: may potentiate GH-releasing effects of hexarelin, requiring dose adjustment
- Both hexarelin and ipamorelin bind the same GHS-R1a receptor. Co-administration provides no additive GH benefit and accelerates receptor desensitization. Choose one GHRP and stack it with a GHRH peptide instead: the most common hexarelin mistake per community consensus.
- Same GHS-R1a receptor. Hexarelin already has the highest binding affinity of any GHRP. At equal doses, it and GHRP-2 raise cortisol and prolactin by similar amounts (PMID 9285939). Combining them compounds these side effects with no additional GH benefit from dual GHS-R1a occupancy.
- Same GHS-R1a receptor. Stacking hexarelin + GHRP-6 is redundant. GHRP-6 adds intense hunger stimulation and cortisol burden with no additive GH benefit over hexarelin alone.
Product Quality
Hexarelin is a 6-amino-acid synthetic peptide (MW ~888 Da): synthesis is relatively straightforward for established peptide manufacturers. No GMP requirement applies to "research use only" peptide products. The compound is genuine GH axis-active; underdosed or impure product produces a measurably blunted IGF-1 response (objectively testable). Pricing range ($14-35 for 2mg; $45-76 for 5mg) indicates moderate market competition with the typical quality variance seen in research peptide categories.
- A credible CoA is batch-specific and comes from a named third-party analytical lab (HPLC purity ≥98% + MS identity confirmation); generic in-house CoAs prove little
- Store lyophilized powder at 2-8°C; refrigerate reconstituted solution and use within 3-4 weeks
- If IGF-1 is not moving after 4-6 weeks of strict fasting compliance and correct reconstitution math, suspect underdosed product before increasing dose: get an IGF-1 lab before escalating
- Verify reconstitution: 5mg vial + 2mL BAC water = 2,500 mcg/mL; 100 mcg = 4 units on U-100 syringe; 200 mcg = 8 units
- Pricing below $10/mg for a 5mg vial of unknown origin is a quality red flag; the typical market range is $9-15/mg
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| IGF-1 | Baseline before starting; repeat at week 4 (end of on-cycle) | Age-adjusted normal range: not supraphysiological. Flag if above upper limit of normal. |
| Fasting glucose | Baseline; repeat at week 4; weekly if pre-diabetic | <100 mg/dL (normal); 100-125 mg/dL warrants dose reduction and closer monitoring |
| Prolactin | Baseline; repeat at week 4 if libido changes or gynecomastia signs emerge | Normal laboratory reference range for sex |
| AM cortisol | Baseline; repeat at week 4 if cortisol symptoms emerge (disrupted sleep, fat gain, irritability) | Normal AM cortisol range (approximately 6-23 mcg/dL at 8 AM) |
| Thyroid (TSH, fT3, fT4) | Baseline; repeat at week 12 of ongoing protocols if symptoms emerge | Not listed |
Primary efficacy marker for sustained GH axis activation. Confirms product quality and dosing adequacy. Detects over-response requiring dose reduction. IGF-1 responds to consistent pulsing within 2-4 weeks.
GH release antagonizes insulin action. Hexarelin-induced cortisol co-elevation further impairs glucose tolerance at higher doses. Essential in any individual with insulin resistance history.
Hexarelin raises prolactin about as much as GHRP-2 does at equal doses (PMID 9285939). Returns to baseline within 2-3h post-injection. In adults given 16 weeks of twice-daily injections, the prolactin response did not change (PMID 10341859). Relevant especially at intermediate/advanced doses.
Hexarelin raises ACTH and cortisol; two human studies found rises similar to GHRP-2 at equal doses (PMID 9285939, 10195374). In adults on 1.5 mcg/kg twice daily for 16 weeks, the cortisol response fell and recovered after stopping (PMID 10341859). Their 24-hour urinary free cortisol did not change. The 300 mcg twice daily protocol lacks long-term data.
GH accelerates T4-to-T3 conversion. Untreated hypothyroidism blunts GH response; GH axis activation can unmask subclinical hypothyroidism.
Hexarelin Before and After
Initial GH pulse detectable within 30 minutes of first dose. Mild hunger increase and possible facial flushing. Sleep quality may begin to improve with evening dosing.
Consistent GH and IGF-1 elevation. Noticeable appetite increase. Mild water retention and potential tingling or numbness at higher doses.
Recovery benefits become apparent. Fat loss and improved sleep solidify. Cortisol and prolactin effects may be noticeable at aggressive doses.
Peak GH response before receptor desensitization sets in. Best body composition changes observed. Transition to off-cycle period recommended.
GHS receptor sensitivity resets over 2-4 weeks. Most body composition gains are retained. GH and IGF-1 gradually return toward baseline.
What to Expect
Days 1 to 3, Initial GH pulse. The GH spike hits within 30 minutes of your first subcutaneous injection, per pharmacokinetic data from Ghigo's 1994 study [1]. Most users notice a warmth and tingling sensation 10 to 20 minutes post-injection. That's the GH flush. Sleep quality often starts improving within the first 2 to 3 doses if you're dosing at bedtime. Mild appetite increase kicks in through the ghrelin pathway. Some users report facial flushing at higher starting doses. Cortisol and prolactin both elevate transiently but return to baseline within 2 to 3 hours.
Weeks 1 to 2, GH and IGF-1 climbing. Consistent GH pulsing with each injection drives IGF-1 upward, measurable on bloodwork by week 2 to 4. Sleep quality improvement solidifies. Recovery between training sessions gets noticeably faster. Mild water retention is common. The appetite bump post-injection is manageable at beginner doses but more pronounced at 200 mcg twice daily. Tingling in extremities may appear at higher doses from GH-mediated fluid retention.
Weeks 2 to 3, peak response window. This is where body composition changes start showing. GH-mediated lipolysis and IGF-1 anabolic signaling have been accumulating for two weeks. Reduced abdominal fat and improved muscle fullness become visible. Recovery from training is well established. If you're running continuous daily dosing without 5-on/2-off weekly breaks, the GH response per injection may already be diminishing. Cortisol and prolactin effects become more noticeable at the 300 mcg aggressive dose level.
Week 4, desensitization threshold. Best body composition results of the cycle are typically visible at this point. The post-injection flush and tingling that was strong in weeks 1 to 2 starts fading. That's not tolerance in the casual sense; it's GHS-R1a receptor downregulation from high-affinity binding. The community strongly recommends transitioning to the off-cycle here. Extending beyond 4 weeks produces diminishing returns with the same side effect burden.
Weeks 5 to 8, off-cycle recovery. Hexarelin clears plasma within hours of the last injection (half-life roughly 70 minutes). GHS-R1a receptor density recovers over 2 to 4 weeks off. The good news: body composition gains from the 4-week cycle are largely retained for 4 to 6 weeks post-cycle. Sleep quality may dip modestly compared to on-cycle. Appetite returns to baseline within days. Water retention resolves. IGF-1 gradually returns toward pre-cycle levels. Most users plan their next cycle after a full 4-week off period.
Detailed Timeline: Science vs Community
GH pulse detectable within 30 min of SC injection per PK data (PMID 8126144). GH promotes slow-wave sleep architecture. Cortisol and prolactin transient elevation returns to baseline within 2-3h post-injection.
Post-injection warmth and tingling within 10-20 min is common (GH flush effect). Sleep improvement often noticed within first 2-3 doses. Mild appetite increase. Some users report facial flushing at higher doses.
Consistent GH pulsing with each injection. IGF-1 begins rising, measurable by week 2-4. GH stimulates slow-wave sleep. Cortisol and prolactin elevation remains transient per injection (PMID 9285939).
Consistent sleep quality improvement with bedtime dosing. Recovery from training noticeably faster. Mild water retention. Appetite increase manageable. Users at 200 mcg 2×/day begin noticing recovery gains.
GH-mediated lipolysis and IGF-1 anabolic signaling accumulate. GHS-R1a desensitization beginning to develop with continuous daily use without 5-on/2-off cycling.
Body composition improvements become visible: reduced abdominal fat, improved muscle fullness. Recovery solidified. Users on continuous protocols (no weekly breaks) start noticing diminishing post-injection response. Cortisol/prolactin effects more noticeable at 300 mcg aggressive doses.
GHS-R1a receptor downregulation progresses with continuous use; peak GH pulse per injection declining. Best timepoint to transition to off-cycle to allow receptor recovery.
Best body composition changes of the cycle visible at week 4. Post-injection flush/tingling diminishing (sign of receptor desensitization). Community strongly recommends not extending beyond this point.
Short plasma half-life (~70 min) means compound clears within hours of last injection. GHS-R1a receptor density recovers over 2-4 weeks off.
Body composition gains (lean mass, reduced fat) largely retained for 4-6 weeks post-cycle. Sleep quality may decline modestly vs. on-cycle. Most users plan next cycle after 4 weeks off. IGF-1 returns toward baseline.
Pharmacokinetics
Source: Human plasma t½ ~55-70 min (Ghigo et al. 1994, PMID 8126144; rat IV t½ 75.9 min, PMID 10611139)
Pharmacokinetics: Active Dose Over Time
t½ = ~70 minDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Hexarelin Legal?
Hexarelin has never received FDA approval for any indication. It reached Phase II clinical trials in the 1990s for GH deficiency and congestive heart failure, but development was discontinued before any regulatory submission. It is currently classified as a research-only compound in the United States.
Hexarelin is not on FDA's 503A bulk drug substances list (21 CFR 216.23), and FDA has not placed it in any compounding category. It is absent from the 503A category lists (updated May 14, 2026) and the 503B category list (updated March 21, 2025). It was not part of the 2026 Category 2 changes or the July 2026 advisory committee meeting.
The compound is sold online as a "for research use only" product. WADA prohibits all growth hormone releasing peptides, including hexarelin, under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Athletes subject to anti-doping testing should not use this compound.
This content is for informational purposes only. Hexarelin is not approved for human therapeutic use. Consult a qualified healthcare provider before considering any peptide protocol.
Evidence grade: Small human studies only (Peptide Evidence Gap, October 2026)
Who Should Consider Hexarelin
- Adults seeking a strong GH pulse for short-term body recomposition cycles
- Individuals interested in peptide-based cardioprotective support (research context)
- Experienced peptide users comfortable managing cortisol and prolactin elevation
- Athletes in short recovery-focused phases who can cycle on and off appropriately
- Researchers studying GHS-R1a and CD36-mediated cardiac signaling pathways
Related Peptides
What Changed for Hexarelin
- Safety
Corrected Oct 17, 2026: the hexarelin cortisol study gives no ages in its abstract, so these pages say adults, not older adults, per Rahim 1999.
Before: In healthy older adults on hexarelin, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859) After: In adults on hexarelin, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859)
What this does not mean: The finding stands: 16 weeks of twice-daily hexarelin lowered the cortisol response and left the prolactin response unchanged. Only the description of the study group changed.
Source: Clin Endocrinol 1999, The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin (Rahim et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 16, 2026: in older adults, 16 weeks of twice-daily hexarelin lowered the cortisol response, not the prolactin response, per Rahim 1999.
Before: At 300 mcg twice daily the cumulative cortisol burden becomes clinically meaningful; at higher twice-daily doses prolactin can rise enough to affect libido After: In older adults on 1.5 mcg/kg twice daily for 16 weeks the cortisol response fell and the prolactin response did not change (PMID 10341859); higher-dose symptoms labelled community reports
What this does not mean: Hexarelin still raises cortisol, ACTH and prolactin after each injection. The 300 mcg twice daily protocol lacks long-term data, and community reports of poor sleep at that dose stay on the page.
Source: Clin Endocrinol 1999, The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin (Rahim et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 16, 2026: hexarelin raises prolactin, ACTH and cortisol by about as much as GHRP-2 at equal doses, not more, per Arvat 1997.
Before: Cortisol and prolactin rises more pronounced than with any other GHRP; Popovic's group confirmed this against GHRP-2 at equivalent doses (PMID 9285939) After: Community reports rank hexarelin worst for both; in Arvat's two small studies, prolactin, ACTH and cortisol rose by similar amounts with hexarelin and GHRP-2 at equal IV doses (PMID 9285939, 10195374)
What this does not mean: Hexarelin still raises prolactin, ACTH and cortisol. The page had credited this paper to Popovic 1995. Human head-to-head data against GHRP-6 or ipamorelin on these hormones are lacking.
Source: Peptides 1997, Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man (Arvat et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 16, 2026: the hexarelin + GHRP-2 warning no longer says hexarelin has the highest cortisol and prolactin rise of any GHRP, per Arvat 1997.
Before: Hexarelin already has the highest binding affinity and cortisol/prolactin elevation of any GHRP After: Hexarelin already has the highest binding affinity of any GHRP; at equal doses it and GHRP-2 raise cortisol and prolactin by similar amounts (PMID 9285939)
What this does not mean: Stacking hexarelin with GHRP-2 is still advised against. Both bind GHS-R1a, add no GH benefit together, and raise cortisol and prolactin.
Source: Peptides 1997, Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man (Arvat et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
Peptide Schedule Research TeamReviewed Apr 7, 202618 Citations
References
- [1]Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after various routes of administration in man (J Clin Endocrinol Metab 1994) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Identification and characterization of a new growth hormone-releasing peptide receptor in the heart (Circ Res 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Effects of GHRP-2 and hexarelin on GH, prolactin, ACTH and cortisol levels in man (Arvat et al., Peptides 1997) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction (Am J Transl Res 2018) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Growth hormone-releasing activity of hexarelin in humans: a dose-response study (Eur J Clin Pharmacol 1995) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]The growth hormone secretagogue hexarelin protects rat cardiomyocytes from in vivo ischemia/reperfusion injury through interleukin-1 signaling pathway (Huang et al., Int Heart J 2017) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [7]CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart (Bodart et al., Circ Res 2002) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [8]Ghrelin plays a minor role in the physiological control of cardiac function in the rat (Torsello et al., Endocrinology 2003) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [9]Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans (Arvat et al., J Endocrinol Invest 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [10]The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin (Rahim et al., Clin Endocrinol 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [11]Impact of two or three daily subcutaneous injections of hexarelin on 24-h GH, prolactin, ACTH and cortisol secretion in humans (Maccario et al., Eur J Endocrinol 2002) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [12]Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects (Berlanga-Acosta et al., Clin Med Insights Cardiol 2017) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [13]GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats (Deghenghi et al., Life Sci 1994) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- FDA: Bulk drug substances nominated for use in compounding under section 503A, categories (updated May 14, 2026) (opens in a new tab)Review
- FDA: Bulk drug substances nominated for use in compounding under section 503B, categories (updated March 21, 2025) (opens in a new tab)Review
- 21 CFR 216.23: Bulk drug substances that can be used to compound drug products under section 503A (eCFR) (opens in a new tab)Review
- Federal Register 2026-07361: Pharmacy Compounding Advisory Committee meeting notice (April 16, 2026) (opens in a new tab)Review
- Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats (Drug Metab Dispos 2000) (opens in a new tab)PubMed 10611139PubMed
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Hexarelin?
Niche. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: Dozens. Community mentions on Reddit: ~dozens of threads.
311 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Low search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.